NuCana is trading at $1.15, up 5.50%, in pre-market; no clear company-specific catalyst was identified for the rise.

  • Its latest listed news is the September 2026 European patent grant for NUC-7738, which predates this move.
  • The patent announcement does not establish a direct cause; the supplied prior-session report also noted no clear company-specific catalyst amid the October 2 decline.
  • Major U.S. index moves for this pre-market were small and mixed, so they do not clearly explain the rise.